In the present study, the heterozygous genotype frequency for the indel rs71305152 in ZFPM2 was revealed in Fig 3 to be significantly decreased in glioma patients compared to controls (P = 0.005), suggesting a potentially protective role played by the heterozygous genotype in gliomas. This evidence concerns the gene ZFPM2 and central nervous system cancer.